Bemotrizinol (PARSOL® Shield / Tinosorb S): Next-Generation Sunscreen Protection

PARSOL® Shield (Bemotrizinol) is a breakthrough in sun protection, providing powerful, broad-spectrum UVA and UVB coverage. Known for its high photostability and effective protection at low concentrations, this filter has been widely used internationally for over 20 years, offering trusted protection in Europe, Asia, and Australia. Now approved by the FDA, it marks a significant milestone in U.S. sun protection technology.

Benefits of PARSOL® Shield

Broad-Spectrum Protection: Offers both UVA and UVB protection, minimizing sun damage that leads to premature aging and skin cancers.
Photostable Formula: PARSOL® Shield retains its protective properties under sunlight, ensuring long-lasting efficacy throughout the day.
Compatibility: Works well with both organic and inorganic sunscreen ingredients, enhancing formulations without compromising their performance.

Why PARSOL® Shield Matters

PARSOL® Shield’s unique formulation allows for less visible residue, making it suitable for a variety of skin tones and types. Its FDA approval provides American consumers access to advanced sun protection, contributing to better skin cancer prevention and public health efforts.

FDA Approval Status

On June 9, 2026, the FDA officially approved bemotrizinol as a new sunscreen active ingredient under its updated Over-the-Counter (OTC) sunscreen monograph standards — the first new active ingredient added to U.S. sunscreens in over 25 years. The approval becomes effective August 9, 2026.

In the U.S., bemotrizinol will initially be sold under DSM-Firmenich’s brand name, PARSOL® Shield, which holds an 18-month period of market exclusivity. Internationally, the same ingredient has been marketed for decades under the name Tinosorb® S by BASF — a name you may already recognize from Korean, Japanese, or European sunscreens.

Now that it’s approved, bemotrizinol-containing sunscreens are expected to begin reaching U.S. shelves later in 2026 and into 2027, giving American consumers access to advanced sun protection technology that’s been trusted abroad for over two decades.

Dr. Jane Yoo Board-Certified Dermatologist and Mohs Surgeon

Jane Yoo, MD, MPP, is a Korean American board-certified dermatologist and fellowship-trained Mohs surgeon based in Midtown Manhattan. She is a Clinical Assistant Professor at the Icahn School of Medicine at Mount Sinai and the founder of Jane Yoo MD, PLLC and the Clinical Research Center of New York. Dr. Yoo holds an undergraduate degree from MIT and a Masters of Public Policy from Harvard's Kennedy School of Government. She completed her Mohs micrographic surgery fellowship at Yale. Her clinical and research focus spans aesthetic clinical trials including injectables and laser technology, skincare formulation and sunscreen science, K-Beauty and skin of color, ultrasound guided filler dissolution, artificial intelligence and beauty tech. Dr. Yoo's research is indexed under ORCID 0000-0002-7112-8963.

See Full Bio